McKesson (NYSE: MCK) reported earnings on April 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q4), McKesson beat expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.

Gross margins shrank, operating margins improved, and net margins improved.

Revenue details
McKesson reported revenue of $31.70 billion. The 12 analysts polled by S&P Capital IQ hoped for revenue of $30.39 billion on the same basis. GAAP reported sales were 9.9% higher than the prior-year quarter's $28.85 billion.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $2.09. The 13 earnings estimates compiled by S&P Capital IQ averaged $2.04 per share. GAAP EPS of $2.09 for Q4 were 30% higher than the prior-year quarter's $1.61 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 5.8%, 30 basis points worse than the prior-year quarter. Operating margin was 2.2%, 10 basis points better than the prior-year quarter. Net margin was 1.6%, 10 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $30.57 billion. On the bottom line, the average EPS estimate is $1.45.

Next year's average estimate for revenue is $123.41 billion. The average EPS estimate is $7.08.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 584 members out of 607 rating the stock outperform, and 23 members rating it underperform. Among 199 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 192 give McKesson a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on McKesson is outperform, with an average price target of $95.97.

The health-care investing landscape is littered with also-rans and a few major winners. Is McKesson prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.